CN102119031B - 肝祖细胞的条件培养基 - Google Patents

肝祖细胞的条件培养基 Download PDF

Info

Publication number
CN102119031B
CN102119031B CN200980131229.6A CN200980131229A CN102119031B CN 102119031 B CN102119031 B CN 102119031B CN 200980131229 A CN200980131229 A CN 200980131229A CN 102119031 B CN102119031 B CN 102119031B
Authority
CN
China
Prior art keywords
cell
hlsc
human
liver
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980131229.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102119031A (zh
Inventor
M.B.赫雷拉桑切斯
V.方萨托
C.特塔
G.卡姆西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Medical Care Deutschland GmbH
Original Assignee
Fresenius Medical Care Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Medical Care Deutschland GmbH filed Critical Fresenius Medical Care Deutschland GmbH
Priority to CN201310348088.1A priority Critical patent/CN103800895B/zh
Publication of CN102119031A publication Critical patent/CN102119031A/zh
Application granted granted Critical
Publication of CN102119031B publication Critical patent/CN102119031B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2053—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN200980131229.6A 2008-06-11 2009-06-11 肝祖细胞的条件培养基 Active CN102119031B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310348088.1A CN103800895B (zh) 2008-06-11 2009-06-11 肝祖细胞的条件培养基

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08010651 2008-06-11
EP08010651.1 2008-06-11
PCT/EP2009/057232 WO2009150199A1 (en) 2008-06-11 2009-06-11 Conditioned medium of liver progenitor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310348088.1A Division CN103800895B (zh) 2008-06-11 2009-06-11 肝祖细胞的条件培养基

Publications (2)

Publication Number Publication Date
CN102119031A CN102119031A (zh) 2011-07-06
CN102119031B true CN102119031B (zh) 2014-09-10

Family

ID=40905279

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980131229.6A Active CN102119031B (zh) 2008-06-11 2009-06-11 肝祖细胞的条件培养基
CN201310348088.1A Active CN103800895B (zh) 2008-06-11 2009-06-11 肝祖细胞的条件培养基

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310348088.1A Active CN103800895B (zh) 2008-06-11 2009-06-11 肝祖细胞的条件培养基

Country Status (12)

Country Link
US (2) US10456425B2 (https=)
EP (1) EP2296672B1 (https=)
JP (1) JP5632833B2 (https=)
CN (2) CN102119031B (https=)
BR (1) BRPI0909866B1 (https=)
CA (1) CA2727392C (https=)
DK (1) DK2296672T3 (https=)
ES (1) ES2556630T3 (https=)
HU (1) HUE028676T2 (https=)
PL (1) PL2296672T3 (https=)
PT (1) PT2296672E (https=)
WO (1) WO2009150199A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2333047A1 (en) 2009-12-09 2011-06-15 Fresenius Medical Care Deutschland GmbH Adult stem cell derived conditioned medium and/or adult stem cells for use in the therapeutic treatment of a tumor disease
US8603470B1 (en) * 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
ES2759228T3 (es) 2013-07-05 2020-05-08 Univ Catholique Louvain Medio acondicionado de células madre de hígado de adultos y su uso en el tratamiento de trastornos del hígado
US10385114B2 (en) 2013-09-05 2019-08-20 Inis Biotech Llc SPARC (secreted protein, acidic and rich in cysteine), a new target for the treatment and prevention of acute liver failure
RU2644650C2 (ru) * 2014-12-01 2018-02-13 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток и способ его получения
CN104818245B (zh) * 2015-05-29 2020-02-04 广州赛莱拉干细胞科技股份有限公司 一种肝脏干细胞的培养基及培养方法
WO2017139455A1 (en) 2016-02-10 2017-08-17 Wake Forest University Health Sciences Model system of liver fibrosis and method of making and using the same
RU2708329C2 (ru) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
JP2021526556A (ja) 2018-05-30 2021-10-07 ダイレクト バイオロジクス エルエルシー 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞（ｍｓｃ）の調製物を含む助剤、ならびにその使用方法
CN109628377A (zh) * 2019-01-02 2019-04-16 贵州省人民医院 一种小鼠原代肝细胞灌注式分离及离体培养方法
CN111607556B (zh) 2019-01-25 2022-06-07 中国科学院广州生物医药与健康研究院 一种培养扩增人肝祖细胞的培养基及其应用
BR112021015549A2 (pt) 2019-02-07 2021-10-26 Direct Biologics Llc Método para tratar osteoartrite com uma combinação de exossomos de células tronco mesenquimais, células tronco mesenquimais sinoviais e andaimes
DK3963050T3 (da) * 2019-04-30 2023-12-11 Cellaion Sa Forberedelse af humane allogene leverderiverede progenitorceller
CN111394391B (zh) * 2019-07-11 2022-12-06 上海赛立维生物科技有限公司 肝祖细胞样细胞库的构建方法及其制备的细胞株与应用
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
US12590310B2 (en) 2020-04-22 2026-03-31 Direct Biologics, Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069449A3 (en) * 1999-05-14 2001-02-08 Advanced Tissue Sciences Inc Conditioned cell culture medium compositions and methods of use
WO2006126219A1 (en) * 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
WO2007141657A3 (en) * 2006-03-07 2008-04-24 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH093099A (ja) * 1995-06-20 1997-01-07 Toyobo Co Ltd マクロファージ刺激蛋白質改変体およびその製造法
US6475490B1 (en) * 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6719969B1 (en) * 1999-08-09 2004-04-13 The Regents Of The University Of Michigan Treatment of liver disease and injury with CXC chemokines
CA2290240C (en) * 1999-11-24 2008-03-11 Stergios Stergiopoulos High resolution 3d ultrasound imaging system deploying a multi-dimensional array of sensors and method for multi-dimensional beamforming sensor signals
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US6916770B2 (en) 2001-04-27 2005-07-12 Polyone Corporation Multi-functional color concentrate compositions
EP1406573A4 (en) * 2001-06-07 2005-03-30 Skinmedica Inc CONDITIONED CELL CULTURE MEDIA AND ITS USES
CA2463914A1 (en) * 2001-10-18 2003-04-24 Ixion Biotechnology, Inc. Conversion of liver stem and progenitor cells to pancreatic functional cells
CA2642664A1 (en) * 2006-02-16 2007-08-30 Burnham Institute For Medical Research Media conditioned by human embryonic stem cells or other progenitor cells and uses therefor
FR2912916B1 (fr) * 2007-02-26 2009-05-22 Oreal Composition cosmetique ou dermatologique comprenant un milieu de culture cellulaire

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069449A3 (en) * 1999-05-14 2001-02-08 Advanced Tissue Sciences Inc Conditioned cell culture medium compositions and methods of use
WO2006126219A1 (en) * 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
WO2007141657A3 (en) * 2006-03-07 2008-04-24 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Banas Agnieszka et al..IFATS collection:in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplatation into mice with liver injury.《Stem Cells》.2008,第26卷(第10期),2705-2712. *
Nowak G et al..Identification of expandable human hepatic progenitors which differentiate into mature hepatic cells in vivo.《GUT》.2005,第54卷(第7期),972-979. *

Also Published As

Publication number Publication date
WO2009150199A1 (en) 2009-12-17
DK2296672T3 (en) 2016-01-04
JP5632833B2 (ja) 2014-11-26
CN103800895B (zh) 2016-12-28
BRPI0909866A2 (pt) 2015-08-11
ES2556630T3 (es) 2016-01-19
CA2727392C (en) 2017-08-22
PT2296672E (pt) 2016-01-22
EP2296672A1 (en) 2011-03-23
EP2296672B1 (en) 2015-09-16
BRPI0909866B1 (pt) 2021-08-24
CN103800895A (zh) 2014-05-21
US20170182100A1 (en) 2017-06-29
US20110129439A1 (en) 2011-06-02
CN102119031A (zh) 2011-07-06
JP2011522553A (ja) 2011-08-04
PL2296672T3 (pl) 2016-03-31
HUE028676T2 (en) 2016-12-28
CA2727392A1 (en) 2009-12-17
US10456425B2 (en) 2019-10-29
US10357519B2 (en) 2019-07-23

Similar Documents

Publication Publication Date Title
CN102119031B (zh) 肝祖细胞的条件培养基
Petrasek et al. Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells
Wang et al. Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism
ES2589311T3 (es) Poblaciones de células que tienen actividad inmunorreguladora, método de aislamiento y usos
Ehrhart et al. Plasma derived from human umbilical cord blood: Potential cell‐additive or cell‐substitute therapeutic for neurodegenerative diseases
CN102686723A (zh) 用于治疗处理肿瘤疾病的成体干细胞衍生的条件培养基和/或成体干细胞
Chang et al. Mulberry leaf extract inhibit hepatocellular carcinoma cell proliferation via depressing IL-6 and TNF-α derived from adipocyte
CN106167789B (zh) 低氧处理的间充质干细胞及其应用
Huang et al. Matrine regulates Th1/Th2 inflammatory responses by inhibiting the Hsp90/NF‐κB signaling axis to alleviate atopic dermatitis
Pan et al. Alternative activation of macrophages by prostacyclin synthase ameliorates alcohol induced liver injury
CN111235107B (zh) 一种用于免疫细胞培养的添加剂、培养基及免疫细胞的培养方法
Li et al. Long-term expanded hepatic progenitor cells ameliorate D-GalN/LPS-induced acute liver failure through repolarizing M1 macrophage to M2-Like phenotype via activation of the IL-10/JAK2/STAT3 signaling pathway
KR101835211B1 (ko) Lps 처리한 지방조직-유래 줄기세포 조정 배지의 제조 방법 및 이를 포함하는 약학 조성물
JP7649070B2 (ja) ラクトバチルスプランタラム由来の多糖体または抽出物を含む組成物
CN119286780B (zh) 一种t细胞的体外培养方法
CN120464572A (zh) 一种用于培养gdt细胞的培养基组合以及培养方法
CN120464571A (zh) 一种用于nk细胞扩增的功能化培养基、培养基组合及培养方法
CN118620839A (zh) 一种用于提高无血清环境下nk细胞扩增和杀伤活性的培养基和方法
TW202034933A (zh) 包含克隆幹細胞的用於治療胰腺炎的藥學組合物
Li et al. Preconditioning mesenchymal stromal cells with flagellin enhances the anti-inflammatory ability of their secretome against lipopolysaccharide-induced acute lung injury
KR20220068148A (ko) 역분화 줄기세포 유래 중간엽 줄기세포로부터 분리된 엑소좀의 제조방법 및 이의 용도
CN121320246A (zh) 一种用于同步扩增多类天然免疫细胞的诱导组合物及应用
CN120549978B (zh) 一种增强型间充质干细胞及外泌体在慢性肾炎肾衰竭中的应用
CN120284972A (zh) 盐酸丁螺环酮在制备抗银屑病的药物中的应用
Liu Expression of tumor necrosis factor and c-fos genes in peritoneal macrophages of hypothyroid mice

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant